Pancreatic Cancer Research

ResearcherCentral South UniversityActive in the last 2 years

Xuejun Gong

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5104129040. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: none · 2025: 4 papers · 2026: 2 papers

Papers 11

  1. Extrapancreatic extension modifies chemotherapy benefit in resected pancreatic ductal adenocarcinoma: a population-based cohort study. Co-author DOI 10.1038/s41598-026-47990-w↗
  2. METTL3-driven m6A modification promotes tumor progression and immune evasion in hypoxic pancreatic cancer by enhancing ADAM10-mediated MICA shedding. Co-author DOI 10.1186/s12967-026-08238-3↗
  3. Early onset pancreatic cancer: A review. Last author DOI 10.1016/j.tranon.2024.102239↗
  4. TGM2-P2RX7 loop promotes gemcitabine resistance in pancreatic cancer by modulating glutamine metabolism and mitophagy. Co-author DOI 10.1038/s41420-025-02922-x↗
  5. Microbiome-metabolome interplay in pancreatic cancer progression: insights from multi-omics analysis. Last author DOI 10.1186/s12943-025-02458-9↗
  6. Noninvasive Computed Tomography-Based Quantification of Tumor Fibrosis Predicts Pancreatic Cancer Response to Gemcitabine/Nab-Paclitaxel. Co-author DOI 10.34133/research.0937↗
  7. Hypoxia promotes immune escape of pancreatic cancer cells by lncRNA NNT-AS1/METTL3-HuR-mediated ITGB1 m6A modification. Last author DOI 10.1016/j.yexcr.2023.113764↗
  8. Correction: MiR-142 modulates human pancreatic cancer proliferation and invasion by targeting hypoxia-inducible factor 1 (HIF-1α) in the tumor microenvironment… Co-author DOI 10.1242/bio.059951↗
  9. Mahanimbine Exerts Anticancer Effects on Human Pancreatic Cancer Cells by Triggering Cell Cycle Arrest, Apoptosis, and Modulation of AKT/Mammalian Target of Ra… Last author DOI 10.12659/msm.911013↗
  10. MiR-142 modulates human pancreatic cancer proliferation and invasion by targeting hypoxia-inducible factor 1 (HIF-1α) in the tumor microenvironments. Co-author DOI 10.1242/bio.021774↗
  11. PREX2 promotes the proliferation, invasion and migration of pancreatic cancer cells by modulating the PI3K signaling pathway. First author DOI 10.3892/ol.2016.4688↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yixiong Li · 3 shared papers, 2025 · strength 0.81
  2. Dong Luo · 3 shared papers, 2025 · strength 0.81
  3. Yebin Lu · 3 shared papers, 2017–2023 · strength 0.57
  4. Wei Wei · 1 shared paper, 2026 · strength 0.39
  5. Shuai Liang · 1 shared paper, 2026 · strength 0.39
  6. Fan Zhang · 1 shared paper, 2026 · strength 0.36
  7. Yebin Lu · 1 shared paper, 2026 · strength 0.36
  8. Ke Ye · 1 shared paper, 2025 · strength 0.30
  9. Shuai Liang · 1 shared paper, 2025 · strength 0.30
  10. Weijia Sun · 2 shared papers, 2017–2023 · strength 0.30
  11. Shuai Zhu · 1 shared paper, 2023 · strength 0.26
  12. Xitao Wang · 1 shared paper, 2023 · strength 0.22
  13. Jun Cheng · 1 shared paper, 2025 · strength 0.19
  14. Yize Mao · 1 shared paper, 2025 · strength 0.19
  15. Lizhi Liu · 1 shared paper, 2025 · strength 0.19
  16. Ningning Niu · 1 shared paper, 2025 · strength 0.19
  17. Xiaoping Yi · 1 shared paper, 2025 · strength 0.19
  18. Peng Luo · 1 shared paper, 2025 · strength 0.19
  19. Qiuxia Yang · 1 shared paper, 2025 · strength 0.19
  20. Chenlin Pei · 1 shared paper, 2018 · strength 0.12
  21. Xitao Wang · 1 shared paper, 2017 · strength 0.08
  22. Jianyi Yang · 1 shared paper, 2016 · strength 0.07
  23. Li Tan · 1 shared paper, 2016 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.